New Research Study Validates Performance and Accuracy of Truvian Sciences’ Easy Check COVID-19 IgM/IgG™ Test
Read More

Watch our webinar with Dr. Jerry Yeo, University of Chicago and Dr. Stephen Rawlings, University of California, San Diego on COVID-19 Antibody Testing.

"Demystifying COVID-19 Antibody Testing"

Rapid Antibody Blood Testing

For organizations with a need for affordable and convenient COVID-19 antibody testing, Truvian's Easy Check COVID-19 IgM/IgG™ antibody test empowers onsite testing at scale, with accurate results at 10 minutes, from a small sample of blood.

To learn more or talk to a member of our team, contact sales@truvianhealth.com

What is the Easy Check COVID-19 IgM/IgG™ Antibody Test?

Easy Check is a serologic test (commonly called an antibody test). Serology is the study of blood in relation to the body's immune response. A serology test can detect the presence of antibodies made by our immune systems to fight active infection, in this case antibodies (IgM and IgG) against the SARS-CoV-2 virus that causes COVID-19.

Why Testing Antibody Levels is Important:

Health experts stress the critical role of antibody testing in the fight against COVID-19 virus. The Easy Check rapid antibody test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. These insights can help individuals understand their exposure history and help people and companies evaluate risk factors when making crucial decisions. Coronavirus antibody testing with Easy Check's rapid results, it can be a powerful tool in monitoring exposure for essential healthcare workers, and serve as a complementary diagnostic test. From a population health perspective, scalable testing data can help inform researchers in their effort to reduce the level of social and economic restrictions globally.

The Easy Check Difference

The Easy Check COVID-19 IgM/IgG antibody test provides significant benefits over traditional lab-based diagnostic technologies.  

Features

  • Compact lateral flow device
  • Fast and easy to use
  • Exceeds the FDA's standards and requirements
  • Results you can trust: 98.4% Sensitivity, 98.9% Specificity
  • Testing sponsored by the National Cancer Institute (NCI): 100% Sensitivity, 97.5% Specificity
  • Cross Reactive Study: 0% cross-reactivity with 15 other infectious diseases including HIV and other coronaviruses
  • Requires only a small patient sample for an accurate antibody test (10uL of whole blood, serum or plasma)
  • Obtain antibody blood test results at 10 minutes
  • No ancillary equipment or training required
  • Affordable economy of scale vs. expensive lab approaches with longer turnaround times
  • Meet service level needs

Product Details

The Easy Check COVID-19 IgM/IgG antibody test is a lateral flow immunochromatographic assay for detection of SARS-CoV-2 IgM/IgG antibodies in human blood, serum or plasma specimens. This accurate antibody test differentiates IgM and IgG immunoglobins (antibodies) specific to SARS-CoV-2 in a single test, rapidly and affordably.

Simple, 3-Step Process, From Sample to Answer

1Deposit 10 uL of blood sample into the handheld testing device.

2Add 1 drop of Assay Buffer.

3Read the test results at 10 minutes.

Part Number

COV-200601

Package Unit

25 Tests/Kit

Part Number

COV-200602-132

Package Unit

132 Kits/Case

Kit Components

25 Test Devices
4mL Assay Buffer
25 Blood Transfer Pipettes
1 Package Insert

Warnings & Precautions

This test to measure coronavirus antibodies has been authorized by FDA under an EUA for use by authorized laboratories that meet requirements to perform moderate or high complexity tests.

This test has not been FDA cleared or approved.

This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens.

This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

This product is intended for professional use and not for home use.

Not for the screening of donated blood.

Frequently Asked Questions

...

Is this test designed to test for active COVID-19, or to identify those who have been previously infected?

Answer

Easy Check COVID-19 IgM/IgG is not for the detection or diagnosis of COVID-19. It is intended for use as an aid in identifying individuals who have antibodies to SARS-CoV-2, and are likely to have previously been exposed to COVID-19. It is important to note that, according to FDA findings, a positive antibody test does not rule out the possibility of a current infection. This test should not be used as the sole criteria for diagnosis of COVID-19.

How is the accuracy of the Easy Check COVIG-19 Igm/IgG test determined?

Answer

The Easy Check COVID-19 IgM/IgG test has been rigorously evaluated in multiple studies by Truvian in collaboration with a number of well-respected institutions, and is designed to meet the variety of standards and requirements set forth by the FDA for EUA. Accuracy specifications are determined by testing confirmed COVID-19 positive and negative samples on the Easy Check COVID-19 IgM/IgG test.

Related Information

...
IFU

Fact Sheet for Healthcare Patients

Fact Sheet for Healthcare Providers